Search research articles
Contact Us
Filters
Showing results (141-150 of 206) with videos related to
Page
of 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 15, 2022
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)
Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper, et al.
Nature Communications
|
September 4, 2023
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
Alexander J Ohnmacht, Arndt Stahler, Sebastian Stintzing, et al.
Molecular Oncology
|
December 4, 2024
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study
Susanne Klein-Scory, Alexander Baraniskin, Wolff Schmiegel, et al.
Oncotarget
|
December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Cancer Cell International
|
September 13, 2025
Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids
Katharina Wansch, Uwe Pelzer, François Schneider, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials
Martin D Berger, Yan Ning, Sebastian Stintzing, et al.
International Journal of Cancer
|
June 2, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer
Satoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, et al.
Molecular Cancer Therapeutics
|
August 7, 2013
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States
Takeru Wakatsuki, Melissa J LaBonte, Pierre O Bohanes, et al.
Annals of Surgical Oncology
|
March 16, 2020
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
Dominik Paul Modest, Volker Heinemann, Gunnar Folprecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Martin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 206) with videos related to
Sort By:
Page
of 21
European Journal of Cancer (Oxford, England : 1990)
|
August 15, 2022
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)
Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper, et al.
Nature Communications
|
September 4, 2023
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
Alexander J Ohnmacht, Arndt Stahler, Sebastian Stintzing, et al.
Molecular Oncology
|
December 4, 2024
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study
Susanne Klein-Scory, Alexander Baraniskin, Wolff Schmiegel, et al.
Oncotarget
|
December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Cancer Cell International
|
September 13, 2025
Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids
Katharina Wansch, Uwe Pelzer, François Schneider, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials
Martin D Berger, Yan Ning, Sebastian Stintzing, et al.
International Journal of Cancer
|
June 2, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer
Satoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, et al.
Molecular Cancer Therapeutics
|
August 7, 2013
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States
Takeru Wakatsuki, Melissa J LaBonte, Pierre O Bohanes, et al.
Annals of Surgical Oncology
|
March 16, 2020
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
Dominik Paul Modest, Volker Heinemann, Gunnar Folprecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Martin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
Page
of 21